Management


Image of Carlos Paya M.D., Ph.D.

Carlos Paya M.D., Ph.D.

President and Chief Executive Officer

Carlos Paya joined Immune Design in May 2011 as our President, Chief Executive Officer and director. He previously served as President of Elan Corporation, a pharmaceutical corporation, which was acquired by Perrigo Company, from November 2008 to April 2011. Before joining Elan Corporation, Dr. Paya was at Eli Lilly & Company, a pharmaceutical corporation, from September 2001 to November 2008, as Vice President, Lilly Research Laboratories. From January 1991 to August 2001, Dr. Paya was Professor of Medicine, Immunology, and Pathology, and Vice Dean of the Clinical Investigation Program at the Mayo Clinic in Rochester, Minnesota. He received his M.D. and Ph.D. degrees from the University of Madrid and underwent postdoctoral training at the Institute Pasteur, Paris, France.

Back

Image of Stephen R. Brady JD, LLM

Stephen R. Brady JD, LLM

Executive Vice President, Strategy & Finance

Stephen R. Brady has been our Executive Vice President, Strategy & Finance since May 2015, and joined Immune Design in September 2013 as our Chief Business Officer. He previously served as Chief Business Officer for 3-V Biosciences, Inc., a biopharmaceutical company, from February 2011 to August 2013, and prior to that, he served as 3-V Bioscience, Inc.'s Vice President, Corporate Development, Strategy and Operations, from February 2010 to February 2011. From April 2007 to March 2010, he was at Proteolix, Inc., a biopharmaceutical company, most recently serving as Vice President, Corporate Development. Prior to Proteolix, Inc., Mr. Brady served as Senior Corporate Counsel at Lexicon Pharmaceuticals, Inc. from 2001 to 2007. Mr. Brady was also a Vice President with Lazard Venture Advisors, a division of Lazard Freres & Co. LLC, from 2000 to 2001, and an associate at Morrison & Foerster LLP from 1996 to 2000. Mr. Brady received a B.A. in English from the University of Oregon, a J.D. from the University of the Pacific and an LL.M. from New York University School of Law.

Back

Image of Adam Craig

Adam Craig

Interim Chief Medical Officer

Adam Craig was appointed Interim Chief Medical Office at Immune Design in June 2016. Dr. Craig is an independent clinical consultant with twenty years of experience in oncology drug development including Chief Medical Officer appointments at Sunesis Pharmaceuticals, Chemgenex Pharmaceuticals (acquired by Cephalon/Teva Pharmaceuticals) and Innovive Pharmaceuticals. As a consultant, Dr. Craig provides strategic and operational clinical and regulatory advice to a number of biotechnology companies, venture firms and investment funds. He currently serves as a Product Reviewer for the Cancer Prevention Research Institute of Texas. Dr. Craig received his medical qualifications from London University, a Ph.D. in molecular medicine from the University of Leeds, and an M.B.A. from the Open Business School in the United Kingdom. Dr. Craig underwent post-graduate training in pediatrics and pediatric oncology and is a member of the Royal College of Pediatrics and Child Health Physicians (UK).

Back

Image of Wayne Gombotz Ph.D.

Wayne Gombotz Ph.D.

Chief Development Officer

Wayne Gombotz joined Immune Design in December 2011 as our Chief Development Officer. He previously served as Vice President Pharmaceutical Operations at Omeros Corporation, a biopharmaceutical company, from May 2005 to October 2011. Before joining Omeros Corporation, Dr. Gombotz held several executive management positions including Vice President, Process Science & Pharmaceutical Development at Corixa Corporation, a biotechnology company, from September 2002 to March 2005 and Sr. Director, Analytical Chemistry and Formulation at Immunex Corporation, a biopharmaceutical company, from April 1993 to September 2002. He was also a staff scientist at Bristol-Myers Squibb and Enzytech Inc. Dr. Gombotz also currently serves as an Advisory Board Chair of the Center for Intracellular Delivery of Biologics and an Advisory Board Member for the University of Washington's Department of Bioengineering. Dr. Gombotz received an M.S. and Ph.D. degree in Bioengineering from the University of Washington where he is an Affiliate Assistant Professor.

Back

Image of Frank J Hsu M.D.

Frank J Hsu M.D.

Vice President, Head of Oncology

Frank Hsu joined Immune Design in October 2013 as Vice President, Head of Oncology. Dr. Hsu recently served as Chief Medical Officer for Zyngenia, Inc., where he was responsible for strategic planning and clinical development of multi-specific, multi-valent agents for the company's lead programs in immune-mediated diseases and oncology. Prior to that, Dr. Hsu was Senior Medical Director at Genzyme in the Transplant and Oncology Division, where for more than nine years he was responsible for the clinical development of products in the areas of hematology, oncology, and stem cell transplant, and supported medical affairs and corporate development. From 1996-2003 he served as an Assistant Professor of Medicine in the Section of Oncology and as co-Director of the Immunology Research Program of the Yale Cancer Center. In addition to his current role, he serves on the Board of Trustees of the Grunebaum Cancer Research Foundation. Dr. Hsu received his B.S. from Stanford University, his M.D. from Harvard Medical School, and his residency training in Internal Medicine at UCSF. He was a clinical and research fellow in Oncology at Stanford University from 1990-1996.

Back

Image of Jan Henrik ter Meulen, M.D., Dr. habil., DTM&H

Jan Henrik ter Meulen, M.D., Dr. habil., DTM&H

Chief Scientific Officer

Jan Henrik ter Meulen joined Immune Design in October 2013 as our Chief Scientific Officer. He previously served as Executive Director of Vaccine Research and Head of Department of Vaccine Basic Research at Merck Research Laboratories, a pharmaceutical company, from April 2008 to September 2013. Prior to Merck, from March 2003 to April 2008, Dr. ter Meulen served as Executive Director Infectious Diseases at Crucell Holland and, from September 2006 to April 2008, as Chief Scientific Officer at Etna Biotech S.r.l., a subsidiary of Crucell. Dr. ter Meulen has an M.D. from Albert Ludwigs University Freiburg im Breisgau, a medical doctorate from Julius Maximilians University Wuerzburg, a higher doctorate from Philipps University Marburg, a Diploma in Tropical Medicine and Hygiene from the London School, and is a board certified in Clinical Microbiology by the Chambers of Physicians, Hamburg Germany.

Back

Image of Christopher Whitmore, CPA

Christopher Whitmore, CPA

Vice President, Finance and Administration

Chris Whitmore joined Immune Design in April 2015 and serves as our Vice President, Finance and Administration. Prior to joining Immune Design, he held various accounting and finance positions, most recently as Senior Director of Finance and Corporate Controller of AcelRx Pharmaceuticals, Inc., a publicly-traded specialty pharmaceutical company, from May 2011 to April 2015. From October 2008 to May 2011, he was at Sangamo BioSciences, a publicly-traded biopharmaceutical company, most recently serving as Corporate Controller.  From October 2002 to May 2008, he was at KPMG, LLP, a global public accounting and professional services firm, most recently serving as Manager, Audit. Mr. Whitmore received a B.A. from the University of California at Santa Barbara. He received his Certified Public Accountant Certification from the state of California and currently holds an active license.

Back

Sergey Yurasov, M.D., Ph.D.

Senior Vice President of Clinical Development and Chief Medical Officer

Back